Last updated November 2, 2026 · Reviewed by the Gala Health team
Side effects reported in published sources
Sermorelin is a 29-amino-acid analogue of growth hormone-releasing hormone. A pharmacology review of its use in children with idiopathic growth hormone deficiency concluded that single intravenous doses and repeated once-daily subcutaneous doses were well tolerated. It named transient facial flushing and pain at the injection site as the most commonly reported adverse events.
The prescribing information for Geref 50, the brand-name sermorelin ampoule, says the same thing in plainer terms. In the Irish Medicines Board summary of product characteristics, facial heat, facial flush, and injection site pain occasionally occur and usually disappear within a few minutes. That label covers a single intravenous dose used as a diagnostic test of pituitary function, not repeated injections at home.
What we could not find is a large published trial that measured side effects of sermorelin itself in healthy adults using it for wellness. The closest adult data are a small trial of a related compound. In a placebo-controlled study of 19 people aged 55 to 71, a modified GHRH(1-29) analog (not sermorelin) was self-injected nightly for 16 weeks, and the authors reported transient hyperlipidemia as the only adverse side effect. That is a different molecule, a small group, and a short study, so treat it as context rather than a safety guarantee.
What the evidence does not tell you
The honest summary is that rates are not established. The pediatric review reflects children with a diagnosed deficiency, studied decades ago. The Geref label reflects a one-time diagnostic injection. Neither describes an adult using a compounded injection several nights a week for months.
Compounding adds another gap. The FDA states that it does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed, so the strength and purity of a compounded product depend on the pharmacy that makes it. Ask your provider which pharmacy supplies it.
Who should not use sermorelin
Gala's intake screens for these exclusions before a provider reviews your case. Sermorelin is not appropriate through our program if any of these apply:
- You are under 25
- You have elevated prolactin or IGF-1
- You have uncontrolled diabetes (A1C over 10%)
- You binge drink (4 to 5 or more drinks per occasion)
- You use opiates
- You have hypothyroidism or take thyroid medication
- You have a known allergy to sermorelin
Some of this matches what the Geref label says. The label lists hypersensitivity to sermorelin or its excipients as a contraindication, advises particular caution in patients with diabetes mellitus or epilepsy, and notes that untreated hypothyroidism or antithyroid medicines can change the response to the drug. It also states that the product should not be used during pregnancy or lactation. Tell your provider if you are pregnant, planning to be, or breastfeeding, along with every medicine and supplement you take.
Injection-site care
Sermorelin at Gala is a subcutaneous injection, which means it goes into the fatty tissue just under the skin. MedlinePlus, from the National Library of Medicine, gives general guidance for any subcutaneous injection. Your provider and the instructions that ship with your medication come first, but these points are standard:
- Good injection areas are the upper arms, the outer upper thighs, and the belly area, at least 2 inches (5 cm) away from the belly button.
- Change the site from one injection to the next, at least 1 inch apart.
- Clean the skin with an alcohol pad before you inject.
- Some soreness at the site is expected.
Because the protocol is typically at bedtime five nights a week, rotating sites matters. Keep track of where you injected last so you do not reuse the same spot.
When to call a doctor
Mild redness or soreness where you injected, or brief facial warmth, fits what the sources describe. Contact your provider if any of the following happens:
- Signs of an infection at the site: redness, swelling, red streaks, or a fever. MedlinePlus advises contacting your health care provider for these.
- A reaction at the site that is severe, spreads, or does not improve
- Flushing or discomfort that keeps coming back or bothers you
- Any new symptom after starting that you cannot explain
Seek emergency care or call 911 for hives, swelling of the face or throat, trouble breathing, or chest pain, which can signal a serious allergic reaction.
Regulatory status
Geref (sermorelin acetate) was once FDA-approved. Its manufacturer told the FDA it was discontinuing the products in 2008, and the FDA withdrew approval of both applications effective June 18, 2009. In a 2013 Federal Register notice, the FDA determined that Geref was not withdrawn from sale for reasons of safety or effectiveness.
Today, sermorelin offered through telehealth is compounded. Compounded medications are not FDA-approved. The FDA list of bulk drug substances nominated for compounding under section 503A (updated May 14, 2026) that we reviewed does not include sermorelin. We draw no conclusion from that other than that sermorelin should not be treated as a product the FDA has found safe and effective for adults seeking longevity benefits.
Questions to ask your provider
- What is the evidence for my specific goal, and how would we know if it is not working?
- Which pharmacy compounds this product, and how is it licensed?
- Do my thyroid, blood sugar, or alcohol history change whether sermorelin is right for me?
- How should I rotate injection sites, and which reactions are expected versus a reason to call?
- When should I stop, and who do I contact if something feels wrong?
To compare it with the other options, see our guide to sermorelin vs. HGH.
How Gala's longevity program works
You complete an online health questionnaire, and a licensed provider reviews it asynchronously, with no video call required. If sermorelin is appropriate, it is a subcutaneous injection you give at home, typically at bedtime five nights a week, with a built-in 2-week break every 6 months. Read about sermorelin at Gala or the full longevity program. To see whether you qualify, start your online longevity intake.
This article is general education, not medical advice. Talk to a clinician about your own health history.
Frequently asked questions
What are the most common sermorelin side effects?
Transient facial flushing and pain at the injection site were the most commonly reported adverse events in the published pediatric review, and the Geref label says facial heat, flush, and injection site pain occasionally occur and usually disappear within minutes. Rates for adults using compounded sermorelin are not established.
Is sermorelin safe for long-term use?
We could not find a published trial that measured the long-term safety of sermorelin in healthy adults. Available data come from children with growth hormone deficiency and from a diagnostic-use label. A provider should review your history, and you should report any symptoms that worry you.
Who should not take sermorelin?
Gala's screening excludes people under 25, and anyone with elevated prolactin or IGF-1, uncontrolled diabetes (A1C over 10%), binge drinking, opiate use, hypothyroidism or thyroid medication use, or a known allergy to sermorelin. The Geref label also advises against use during pregnancy or lactation.
When should I call my doctor about an injection site reaction?
Contact your provider for redness, swelling, red streaks, or a fever, which can signal an infection, or for any reaction that is severe or keeps getting worse. Call 911 for hives, swelling of the face or throat, trouble breathing, or chest pain.
Is sermorelin FDA-approved?
Not as a product on the market today. The brand-name Geref was approved but discontinued, and approval was withdrawn in 2009. The FDA determined that was not for reasons of safety or effectiveness. Compounded medications are not FDA-approved.
Ready to talk to a provider?
Your answers go to a licensed provider, who decides whether treatment is right for you. Learn more about Longevity.
Sources
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999.
- Irish Medicines Board. Geref 50 (sermorelin acetate): Summary of Product Characteristics. 2006.
- Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997.
- MedlinePlus. Subcutaneous (SQ) injections. National Library of Medicine.
- Federal Register. Determination That GEREF (Sermorelin Acetate) Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness. March 4, 2013.
- FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (updated May 14, 2026).
- FDA. Compounding and the FDA: Questions and Answers.
This article is for general information and is not medical advice. Talk to a licensed provider about your own health.